Industry

Near Field Communication Medical Device Markets Report 2022: Security, The Energy Issue, RFID Communication, Wireless Architectures, Applications for NFC – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Medical Device Markets for Near Field Communication” report has been added to ResearchAndMarkets.com’s offering. For self-administration, adherence with drug therapy and disease management protocols has become a primary concern within the healthcare and pharmaceutical industries. For chronic conditions adherence has a direct effect on the patient’s quality-of-life. Connected devices – drug injection devices … [Read more…]

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

DALLAS–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases announces that Dr. Hubert Chen, MD has joined the company as Chief Scientific Officer and President. “Dr. Chen is a very accomplished drug development scientist and physician and we are very fortunate that he has agreed to join the Forte team,” … [Read more…]

Soleo Health Named a Limited Drug Distribution Partner by Mitsubishi Tanabe Pharma America for RADICAVA ORS®

Company Named as a Specialty Pharmacy to Distribute Newly FDA-Approved Oral Suspension Treatment for Amyotrophic Lateral Sclerosis (ALS) FRISCO, Texas–(BUSINESS WIRE)–#ComplexCare—Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it was named one of only four limited distribution drug (LDD) specialty pharmacy partners to dispense nationwide RADICAVA ORS® (edaravone) … [Read more…]

Rhinostics Announces First Close of its Series A-2 Financing Round, Led by Shadow Capital

Funds Will Accelerate Market Penetration and Novel Technology Development to Improve Diagnostic Sample Collection and Processing Workflows WALTHAM, Mass.–(BUSINESS WIRE)–#acceleratecovidtesting–Rhinostics Inc., pioneers in bringing efficiencies to sample collection through modernized technologies, announced the first closing of its Series A-2 financing round, led by Shadow Capital, a new life science technology-focused venture firm making investments in … [Read more…]

Engrail Therapeutics Announces Positive Results of ENX-101 Phase 1b Clinical Study and Prepares for Initiation of ENACT Phase 2 Trial in Focal Epilepsy

ENX-101 exhibited a favorable safety and pharmacokinetic profile in healthy volunteers ENX-101 was well tolerated following once-daily oral administration with no dose titration Translational biomarker data indicated target engagement consistent with anti-seizure activity Engrail plans to initiate the ENACT phase 2 trial in epilepsy SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company … [Read more…]

Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases

– Round led by Northpond Ventures with participation from new investors Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors – Proceeds will enable Code Bio to advance its lead programs in Duchenne Muscular Dystrophy (DMD) and type 1 diabetes (T1D) towards IND-enabling studies, expand its pipeline and platform applications, and further scale … [Read more…]

Thomas H. Lee Partners Appoints Sam Hendler As Head of Business Development, Healthcare

Industry Veteran Will Lead Sourcing Strategy for the Firm’s Healthcare Group BOSTON–(BUSINESS WIRE)–Thomas H. Lee Partners, L.P. (“THL”), a premier private equity firm investing in middle-market growth companies, today announced the appointment of Sam Hendler as Managing Director and Head of Business Development for the firm’s healthcare investment group. Hendler, who brings over 20 years … [Read more…]

Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology

Interim results show improved symptoms of psychosis in patients with chronic TRS Study 014 represents first international trial of a New Chemical Entity (NCE) antipsychotic as an add-on in TRS, with treatment implications for TRS patients Newron to host an investor, analyst and media conference call today at 3 pm CET/ 9 am ET Ad … [Read more…]

Cosette Pharmaceuticals Receives U.S. Patent (US 11,291,628) For Welchol® Chewable Bar, A Novel Oral Drug Delivery System to Deliver Colesevelam Hcl

Innovating Every Day.TM BRIDGEWATER, N.J.–(BUSINESS WIRE)–#chewable–Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,291,628 for Welchol® Chewable Bar, the Company’s novel drug delivery system of Colesevelam that is easy to handle and ingest, which provides patent protection until 2037. “Cosette … [Read more…]

STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer® Lens (ICL)

Milestone Follows U.S. FDA Approval of EVO Visian® ICL in March EVO Offers Visual Freedom from Glasses and Contact Lenses LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than two million Visian® Implantable Collamer lenses … [Read more…]